Newsroom

Announcements, media coverage and publications

Get in touch

1 Feb 2024

Possible Polymer Delivery Systems Outnumber the Stars

The convergence of polymer chemistry, materials science, biology, and computation lets scientists assess a plethora of polymer delivery options

Read more

27 Nov 2023

Top ten news stories in 2023

Our ranking is out, and it has a few surprises. In pole position — predictably — is Wegovy, the weight-slashing GLP-1 agonist, with AI-hallucinated proteins a close second. These are followed by drugging options for RNA. The dark horses are virus-free gene therapies and a sweet protein.

Read more

25 Oct 2023

Revolutionizing Gene Therapy Delivery

An early-stage company is using machine learning to design bespoke nonviral delivery methods for future gene therapies. Nanite, set up two years ago, plans to use machine learning to design polymers tailored to gene therapies. The company hopes the polymers can replace viral vectors, as a simpler-to-manufacture way of delivering gene therapies into cells.

Read more

14 Jun 2023

Why gene therapies must go virus-free

Now companies are replacing the virus in gene therapies with new delivery technologies that promise not only to overcome the limitations of viral vectors but to slash production costs too.

Read more

15 Mar 2023

Cystic Fibrosis Foundation Funds Nanoparticle Delivery to Lung

The field of genetic therapies seems to be making a collective shift toward the exploration of delivery systems—and the Cystic Fibrosis Foundation (CFF) is no different. The nonprofit recently announced that they are making an investment of up to $2 million to explore a novel method to deliver genetic therapies to the lung.

Read more

20 Feb 2023

Nanite nabs $6 million to debut AI platform for polymer design

Boston-based startup Nanite has netted $6 million in seed funding to launch its artificial intelligence platform for gene delivery. Founded in 2021, the company applies machine learning to designing polymer nanoparticles for nonviral delivery of genetic therapies.

Read more

We love talking non-viral delivery

Contact us to learn more about what we do.

Get in touch